Shane Thomas Gleason, InspireMD, Inc.'s Chief Commercial Officer, disposed of 61,934 shares of the company's common stock during a series of transactions executed from January 15 through February 2, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The aggregate proceeds from the sales amounted to $99,330. Transaction prices recorded on the filing ranged from $1.574 per share to $1.664 per share. The filing indicates the share dispositions were carried out under a pre-arranged automatic sales instruction letter and were intended to satisfy tax withholding obligations associated with the vesting of restricted stock grants.
After these transactions were completed, Gleason was shown as directly owning 1,139,177 shares of InspireMD. The Form 4 was signed on Gleason's behalf by Michael Lawless, Attorney-in-Fact.
In a separate disclosure of company performance, InspireMD released results for its third quarter of fiscal 2025. The company reported earnings per share of -0.17, which was above the analyst expectation of -0.25. Quarterly revenue was reported at $2.5 million, representing a 39% increase compared with the same quarter in the prior year.
Those financial figures were noted in the filing and subsequent reporting as a positive development for InspireMD. The company’s third-quarter results met or exceeded the earnings projections referenced in the filing, and the revenue growth was presented as a clear year-over-year increase.
Summary
This set of filings records an insider sale by a senior executive executed to cover tax liabilities arising from vested restricted stock awards. The company also disclosed third-quarter results showing an earnings beat and double-digit revenue growth year over year.
Key points
- Gleason sold 61,934 shares between January 15 and February 2, 2026, generating $99,330 at prices between $1.574 and $1.664.
- Sales were made to satisfy tax withholding obligations tied to vested restricted stock grants under a pre-arranged automatic sales instruction.
- InspireMD reported Q3 2025 EPS of -0.17 versus an expected -0.25 and revenue of $2.5 million, a 39% year-over-year increase.
Risks and uncertainties
- The Form 4 indicates the disposals were for tax-withholding purposes; the filing does not provide further detail on any additional planned insider transactions.
- While the quarter’s results beat expectations, they remain negative on an earnings-per-share basis, underscoring continued operating losses.
- The filing and earnings disclosure do not include forward-looking guidance or commentary on upcoming quarters, leaving future performance unclear.